Innovation in European healthcare – what can Sweden learn? - LIF

The evaluation of new products by the HAS.
Evolution of calculated medical benefit
• The vast majority of drugs are covered at a 65%
rate. In 2009, among the 109 new drugs
reviewed by the Transparency Commission, the
vast majority of new drugs were evaluated with
major or considerable therapeutic value (90)
while only 10 were deemed insufficient
– SMR judged sufficient in more than 90%
cases
– BUT No clinical added value for more than
60% of new drugs/new indications: decreased
proportion of drugs with “significant” added
value ( ASMR: moderate to major, I to III)
• Following the creation in 2010 of the 15% rate of
coverage for drugs with low SMR, the
reimbursement rate of 171 additional drugs has
been lowered from 35% to 15%.
• HAS: 84 days was the average time for issuing
guidance in 2011
50%
40%
30%
20%
10%
0%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Drugs’ Evaluation
% of new products or indications with ASMR I, II, III
39%
31%
34%
17% 18%
13%
2005 2006 2007 2008 2009 2010
Medical Devices’ Evaluation
I
II
III
IV
V
2005-2007 2008-2010 2011
98